Endo Tries Its Luck With The Irish Through $1.6 Billion Paladin Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma will expand its global footprint, continue its re-transformation into a specialty pharma business, and gain an appealing new tax rate through the acquisition of Montreal-based Paladin Labs.